Reviva Net Income Per Share from 2010 to 2026

RVPH Stock  USD 0.29  0.01  3.33%   
Reviva Pharmaceuticals' Net Loss is decreasing with slightly volatile movements from year to year. Net Loss is predicted to flatten to -1.09. For the period between 2010 and 2026, Reviva Pharmaceuticals, Net Loss quarterly trend regression had median of (0.82) and r-value of (0.40). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(1.04)
Current Value
(1.09)
Quarterly Volatility
0.2915295
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 37.2 M, Interest Expense of 15.8 K or Selling General Administrative of 4.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 69.77. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Reviva Stock
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.
The Net Income Per Share trend for Reviva Pharmaceuticals Holdings offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Reviva Pharmaceuticals is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Reviva Pharmaceuticals' Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Reviva Pharmaceuticals Holdings over the last few years. It is Reviva Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Reviva Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

Reviva Net Income Per Share Regression Statistics

Arithmetic Mean(0.91)
Coefficient Of Variation(32.05)
Mean Deviation0.20
Median(0.82)
Standard Deviation0.29
Sample Variance0.08
Range1.3441
R-Value(0.40)
Mean Square Error0.08
R-Squared0.16
Significance0.11
Slope(0.02)
Total Sum of Squares1.36

Reviva Net Income Per Share History

2026 -1.09
2025 -1.04
2024 -0.9
2023 -1.65
2022 -1.25
2021 -0.58
2020 -1.24

About Reviva Pharmaceuticals Financial Statements

Investors use fundamental indicators, such as Reviva Pharmaceuticals' Net Income Per Share, to determine how well the company is positioned to perform in the future. Although Reviva Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Loss(1.04)(1.09)

Currently Active Assets on Macroaxis

When determining whether Reviva Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Reviva Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Reviva Pharmaceuticals Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Reviva Pharmaceuticals Holdings Stock:
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is there potential for Biotechnology market expansion? Will Reviva introduce new products? Factors like these will boost the valuation of Reviva Pharmaceuticals. Anticipated expansion of Reviva directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.43)
Return On Assets
(1.30)
Return On Equity
(9.16)
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Reviva Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Reviva Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Reviva Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.